ArticleScientific reports2026
A token efficient vision framework using patch residual transformer for Alzheimer's disease diagnosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, and early diagnosis using structural magnetic resonance imaging (sMRI) is crucial for timely intervention. Recently, the Vision Transformer (ViT) has been applied to sMRI-based AD diagnosis, but it often struggles with information redundancy when handling high-dimensional data, leading to focus loss and missed critical features. To address this, we proposed a Patch Residual Transformer (PRT)-a token-efficient vision framework designed for AD diagnosis and the prediction of mild cognitive impairment (MCI) conversion (i.e., stable MCI vs. progressive MCI). The PRT model partitions sMRI into patches and incorporates a novel Patch Residual Block (PRB), which includes two key components: Top-K patch selection and linear stitch patch token fusion (LSPTF). Top-K component meticulously assesses and ranks patches to identify the most crucial ones for AD diagnosis and MCI conversion prediction. The LSPTF employs retention and linear stitch strategies that enable ViT to concentrate on the most critical regions, thereby avoiding focus loss, achieving patch diversification, optimizing model performance, and accelerating training. We validated our method on two large-scale datasets, Alzheimer's Disease Neuroimaging Initiative (ADNI) and Open Access Series of Imaging Studies-3 (OASIS-3). Our results demonstrate that PRT outperforms existing slice-, patch-, ROI-, and subject-level approaches in both AD diagnosis and MCI conversion prediction. Additionally, the model demonstrates strong generalization and robust salience map consistency across datasets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.